ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Annual Earnings
SPRY·Reported March 20, 2025·Before market open
ARS Pharmaceuticals, Inc. reported Q4 2024 revenue of $86.6M, beat analyst consensus of $12.8M by $73.7M. Diluted EPS came in at $0.52, beat the $-0.04 consensus by $0.56.
Revenue
$86.6Mbeat by $73.7M
Consensus: $12.8MDiluted EPS
$0.52beat by $0.56
Consensus: $-0.04
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about ARS Pharmaceuticals, Inc.'s Q4 2024 earnings report.
ARS Pharmaceuticals, Inc. (SPRY) reported Q4 2024 earnings on March 20, 2025 before market open.
ARS Pharmaceuticals, Inc. reported revenue of $86.6M and diluted EPS of $0.52 for Q4 2024.
Revenue beat the consensus estimate of $12.8M by $73.7M. EPS beat the consensus estimate of $-0.04 by $0.56.
You can read the 10-K periodic report (0000950170-25-042320) directly on SEC EDGAR. The filing index links above go to sec.gov.